Glaucoma medications go the distance

Article

Dorzolamide/timolol fixed combinations (DTFC) and latanoprost achieve consistent 24-hour intraocular pressure (IOP) control and obtain a significant increase in 24-hour diastolic ocular perfusion pressure over a six-month treatment period, according to Anastasios Konstas from the AHEPA Hospital, Thessaloniki, Greece.

Dorzolamide/timolol fixed combinations (DTFC) and latanoprost achieve consistent 24-hour intraocular pressure (IOP) control and obtain a significant increase in 24-hour diastolic ocular perfusion pressure over a six-month treatment period, according to Anastasios Konstas from the AHEPA Hospital, Thessaloniki, Greece.

Fifty-three patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) with an average 24-hour IOP of 25.2±2.3 mmHg were enrolled to take part in a prospective, single-masked, crossover study.

At six-months, the 24-hour IOP for those in the DTFC group was 18.2±1.9 mmHg and 18.3±1.9 mmHg for those in the latanoprost group. However, DTFC demonstrated superior IOP reduction at 10:00 hours (-0.8 mmHg, p=0.01) and at 22:00 hours (-1.1 mmHg, p<0.0001).

These results demonstrated that DTFC and latanoprost remain effective 24-hour treatments for glaucoma, even after six-months' intensive treatment.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.